Who we are
Medicines for Europe
Purpose and Objectives
OUR VALUES
STRUCTURE
OUR MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
JOB OPPORTUNITIES
Key topics
COVID-19
Access
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
Factsheets
Infographics
Reports
Policy
Videos
Podcast
Newsroom
Press releases
In the news
Press kit
Contact us
Login
Generic medicines
Home
Who we are
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Who we are
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Environment of value added medicines in Europe
Definition
THERAPEUTIC AREAS
Q&A
What’s new
Environment of value added medicines in Europe
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Value Added Medicines award 2019
QUOTES
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Newsroom
Filters:
Value added medicines
x
2020
x
News about
By type
In the news
Press releases
By year
2022
2021
2020
2019
2018
2017
2016
2015
2014
Twitter
Tweets
Videos
Photos
Best practice guidance on how to protect workers in relation to Covid-19
20 March 2020
Open
Critical to keep the supply chain of essential medicines manufacturing operating at full capacity
18 March 2020
Open
EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms
18 March 2020
Open
Medicines for Europe update regarding medicines production and supply related to Covid-19
18 March 2020
Open
Medicines for Europe urgent requests to Interior & Transport ministries regarding medicines production and supply
16 March 2020
Open
Medicines for Europe statement on COVID-19 (‘coronavirus’)
13 March 2020
Open
European Industries welcome an important industry focus from the European Commission
11 March 2020
Open
Coordination with industry on potential impact of Covid-19 on medicines manufacturing and supplies in Europe
10 March 2020
Open
Impact of COVID-19 on active ingredient and medicines manufacturing and supplies in Europe
18 February 2020
Open
Resolving and mitigating medicine shortages in the EU
10 February 2020
Drug shortages can greatly impact patients and the pharmaceutical industry. […]
Read more
Posts navigation
1
2
3
4
Subscribe to our newsletter
Tweet
Tweet
Tweet
LinkedIn
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok